Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Slothuus, U.
Right arrow Articles by Brooks, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slothuus, U.
Right arrow Articles by Brooks, R. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 791-799
© 2000 British Society for Rheumatology

Willingness to pay in arthritis: a Danish contribution

U. Slothuus and R. G. Brooks

University of Southern Denmark, Odense University, Institute of Public Health, Health Economics, Winsløwparken 19, 3, DK-5000 Odense C, Denmark

Objective. To explore the use of willingness-to-pay (WTP) methods with respect to an antagonist of tumour necrosis factor as an antirheumatic drug.

Methods. One hundred and fifteen rheumatoid arthritis (RA) patients at a tertiary care centre in Odense, Denmark were interviewed using two WTP approaches, the contingent ranking and double-bounded (closed-ended) methods.

Results. The average closed-ended WTP value was DKr581 and the average contingent ranking WTP was DKr643. There were no statistically significant differences in the WTP estimates between the two methods.

Conclusion. It is feasible to use these methods with arthritis patients. If, as suggested in a number of recent reviews, a major effort is to be put into undertaking economic appraisals of arthritis programmes, then this should include more cost–benefit studies using WTP approaches of the kind illustrated in this paper.

KEY WORDS: Rheumatoid arthritis, TNF-{alpha} blockade, Willingness to pay, Economic appraisal, Cost–benefit analysis.

Correspondence to: Ulla Slothuus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Med Decis MakingHome page
B. Fautrel, A. E. Clarke, F. Guillemin, V. Adam, Y. St-Pierre, T. Panaritis, P. R. Fortin, H. A. Menard, C. Donaldson, and J. R. Penrod
Costs of Rheumatoid Arthritis: New Estimates from the Human Capital Method and Comparison to the Willingness-to-Pay Method
Med Decis Making, March 1, 2007; 27(2): 138 - 150.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.